News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sterion, Inc. (STEN) Reports Second Quarter 2004 Results And Earnings Outlook


10/19/2005 5:11:17 PM

MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- Sterion Incorporated , a Minneapolis-based medical products and emergency services company, today reported results for the second fiscal quarter ended March 31, 2004. Sales for the second quarter ended March 31, 2004 were $2,520,191 a 2.16% increase over the $2,467,885 in sales reported for the second quarter ended March 31, 2003.

Net income for the second quarter ended March 31, 2004, was $1,406 or $0.00 per diluted share, compared to net income of $29,137 in the year earlier, or $.02 per diluted share. Second quarter operating income decreased to a profit of $49,086 compared to a profit of $79,340 for the second quarter of last year. The company's gross margin percentage declined over the first quarter of last year to 43.96% from 44.17%. The decline in gross margin is principally the result of increased private-label business and the transition to contract manufacturing margin for the sterilization container system business. The overall increase in operating income is principally the result of the company's continuing efforts to reduce operating expenses.

Second quarter results include the company's recently-formed LifeSafe Services, Inc. subsidiary. LifeSafe acquired certain assets and liabilities of SOS International effective November 26, 2003. During the second quarter, LifeSafe billed customers $584,275 for service contract fees. The majority of this amount, $359,385 was recorded as deferred revenue and will be recognized as revenue over the contract service periods, generally from 3 to 12 months. Given the deferral nature of service fees, it is expected that both realized and deferred revenue will increase in future periods. As the deferred revenue amounts are included in the results for future periods, overall results will be impacted favorably.

Commenting on the second-quarter results, Kenneth Brimmer, company Chairman and CEO, noted, "Although we continued to see only modest growth in revenue for the quarter, we made important progress in several areas. Our private-label business continued to grow and we added an additional important private-label relationship in the quarter. We are confident that ongoing cost- reduction efforts will improve the bottom-line results for the remainder of the year. Finally, our LifeSafe business is performing as expected and we look forward to an increased contribution to profitability from this business in future periods."

Sterion also announced that based upon preliminary estimates for the fiscal year ending September 30, 2005, it anticipates that total revenue will exceed $11 million and that earnings per share will be in the range of $.35 to $.40 per share. Earnings estimates are based on a combination of current sales revenue trends, including a growing contribution from LifeSafe Services, ongoing margin improvement from production automation investments and new product development. Current estimates for the fiscal year ending September 30, 2004 show total revenue of approximately $9.9 million with earnings per share in the range of $.08 to $.10 per share.

Sterion Incorporated, headquartered in Minnesota, develops, manufactures, assembles and markets single-use medical products and through its LifeSafe Services subsidiary provides emergency oxygen and related services to over 4,000 customers. The company's Surgidyne Division markets surgical wound drainage products offering innovative solutions to surgical wound care. Sterion also provides contract manufacturing services to a major medical equipment corporation for its surgical instrument container sterilization system.

Sterion Incorporated common stock is traded on the Nasdaq SmallCap Market under the symbol STEN. More information about Sterion is available at the Company's website: http://www.sterion.com/ .

Except for historical information contained herein, the disclosures in this news release are forward-looking statements that could be affected by certain risks and uncertainties, and actual results may differ materially, depending on a variety of factors. These risks are described in the Company's Annual Report on Form 10-KSB for the year ended September 30, 2003 and other filings. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions.

All forward-looking statements attributable to us or a person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We are under no duty or obligation to update any of the forward- looking statements after the date of this release.

Sterion Incorporated and subsidiaries Condensed Consolidated Balance Sheets March 31, 2004 Sept. 30, 2003 ASSETS (unaudited) (audited) Current assets Cash and cash equivalents $ 807,360 $1,762,819 Accounts receivable, net 1,775,484 996,229 Inventory, net 3,231,430 3,176,910 Other current assets 548,809 412,901 Total current assets 6,363,083 6,348,859 Property and equipment, net 3,709,951 1,568,847 Other assets 1,669,384 515,895 Total assets $11,742,418 $8,433,601 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities $3,567,525 $1,150,670 Long-term obligations, less current maturities 1,936,395 1,236,933 Deferred income taxes 44,000 44,000 Shareholders' equity 6,194,498 6,001,998 Total liabilities and shareholders' equity $11,742,418 $8,433,601 Sterion Incorporated and subsidiaries Condensed Consolidated Statements of Operations (unaudited) For the Three Months For the Six Months Ended March 31, Ended March 31, 2004 2003 2004 2003 Sales, net $2,520,191 $2,467,885 $4,903,953 $4,696,622 Cost of goods sold 1,412,388 1,377,717 2,950,408 2,479,948 Gross profit 1,107,803 1,090,168 1,953,545 2,216,674 Selling, general and administrative expenses 1,058,717 1,010,828 1,901,609 2,168,737 Income from operations 49,086 79,340 51,936 47,937 Other income (expense) Interest expense (49,299) (34,245) (82,209) (69,001) Other income 1,619 42 5,700 133 Total other income (expense) (47,680) (34,203) (76,509) (68,868) Income (loss) before income taxes 1,406 45,137 (24,573) (20,931) Provision for (benefit from) income taxes - 16,000 (9,000) (7,000) Net income (loss) 1,406 29,137 (15,573) (13,931) Net income (loss) per share: Basic $.00 $.02 $(.01) $(.01) Diluted $.00 $.02 $(.01) $(.01) Weighted average common and common equivalent shares outstanding: Basic 1,738,618 1,729,537 1,738,527 1,729,537 Diluted 1,879,806 1,786,849 1,738,527 1,729,537

Sterion Incorporated

CONTACT: Robbin Metz of Sterion Incorporated, +1-763-259-6827


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES